Introduction: Post-transplant lymphoproliferative disease (PTLD) comprises a variety of lymphoid and plasma cell disorders arising in patients with a solid organ transplant. Monomorphic lymphomas represent the most significant part of this wide spectrum, with the overall risk rising with the aggressiveness of lymphoid proliferation in comparison to the general population. The development of Hodgkin lymphoma is very rare in transplant recipients, comprising less than 6% of all monomorphic PTLD, while cases of primary intestinal Hodgkin lymphoma in these circumstances are anecdotal. Case Report: We describe an exceptional case of intestinal Hodgkin lymphoma mimicking an intra-abdominal abscess that developed in a transplant recipient 19 years after kidney transplantation. By presenting this case, we wish to emphasize the importance of suitable diagnostic pathways in transplant recipients experiencing prolonged fever episodes or masses of unknown origin, thus raising the awareness of possible PTLD development in such patients. Conclusion: The lack of information about transplant recipients with Hodgkin PTLD regarding the site of involvement and type of treatment suggests the necessity of conducting larger international studies aimed at providing further insight into this particular group of patients.

1.
Al-Mansour Z, Nelson BP, Evens AM: Post-transplant lymphoproliferative disease (PTLD): Risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep 2013;8:173-183.
[PubMed]
2.
Clarke CA, Morton LM, Lynch C, Pfeiffer RM, Hall EC, Gibson TM, Weisenburger DD, Martínez-Maza O, Hussain SK, Yang J, Chang ET, Engels EA: Risk of lymphoma subtypes after solid organ transplantation in the United States. Br J Cancer 2013;109:280-288.
[PubMed]
3.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW: WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press, 2008.
4.
Quinlan SC, Landgren O, Morton LM, Engels EA: Hodgkin lymphoma among US solid organ transplant recipients. Transplantation 2010;90:1011-1015.
[PubMed]
5.
Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM: Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 2007;370:59-67.
[PubMed]
6.
Opelz G, Dohler B: Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2003;4:222-230.
[PubMed]
7.
Caillard S, Lamy FX, Quelen C, Dantal J, Lebranchu Y, Lang P, Velten M, Moulin B; French Transplant Centers: Epidemiology of posttransplantlymphoproliferative disorders in adult kidney and kidney pancreas recipients: Report of the French Registry and Analysis of Subgroups of Lymphomas. Am J Transplant 2012;12:682-693.
[PubMed]
8.
Caillard S, Agodoa LY, Bohen EM, Abbott KC: Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: Characteristics, risk factors and prognosis. Transplantation 2006;81:888-895.
[PubMed]
9.
Penn L: Neoplastic complications of transplantation. Semin Respir Infect 1993;8:233-239.
[PubMed]
10.
Saadat A, Einollahi B, Ahmadzad-Asl MA, Moradi M, Nafar M, Pourfarziani V, Firoozan A, Porrezagholi F, Davoudi F: Posttransplantation Lymphoproliferative Disorders in Renal Transplant Recipients: Report of Over 20 Years of Experience. Transplant Proc 2007;39:1071-1073.
[PubMed]
11.
Rosenberg AS, Klein AK, Ruthazer R, Evens AM: Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival. Am J Hematol 2016, 91:560-565.
[PubMed]
12.
Gandhi JS, Mehta A, Sharma A, Kamboj M: Primary Hodgkin lymphoma of the ileum. J Cancer Res Ther 2010;6:342-343.
[PubMed]
13.
Morgan PB, Kessel IL, Xiao SY, Colman M: Uncommon presentations of Hodgkin's disease. Case 1. Hodgkin's disease of the Jejunum. J Clin Oncol 2004;22:193-195.
[PubMed]
14.
Pai SA, Naresh KN, Borges AM: Primary Hodgkin's disease of the small intestine: Does it really exist? Indian J Gastroenterol 1994;13:150.
[PubMed]
15.
Cerilli J, Rynasiewicz J, LemosL, Rothermel WS Jr: Hodgkin's disease in human renal transplantation. Am J Surg 1977;133:182-184.
[PubMed]
16.
Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K: Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005;80:1233-1243.
[PubMed]
17.
Morscio J, Dierickx D, Tousseyn T: Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: What do we know so far? Clin Dev Immunol 2013;2013:150835.
[PubMed]
18.
McDonald RA, Smith JM, Ho M, Lindblad R, Ikle D, Grimm P, Wyatt R, Arar M, Liereman D, Bridges N, Harmon W; CCTPT Study Group: Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008;8:984-989.
[PubMed]
19.
Cockfield SM: Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001;3:70-78.
[PubMed]
20.
Jagadeesh D, Woda BA, Draper J, Evens AM: Post transplant lymphoproliferative disorders: Risk, classification, and therapeutic recommendations. Curr Treat Options Oncol 2012;13:122-136.
[PubMed]
21.
Doak PB, Montgomerie JZ, North JD, Smith F: Reticulum cell sarcoma after renal homotransplantation and azathioprine and prednisone therapy. Br Med J 1968;4:746-748.
[PubMed]
22.
Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, Rosenthal JT, Hakala TR, Shaw BW Jr, Hardesty RL, Jaffe R, Bahnson HT: Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984;1:583-587.
[PubMed]
23.
Swinnen LJ, LeBlanc M, Grogan TM, Gordon LI, Stiff PJ, Miller AM, et al.: Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation 2008;86:215-222.
[PubMed]
24.
Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW: Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol 2009;27:3354-3362.
[PubMed]
25.
Podoltsev N, Zhang B, Yao X, Bustillo I, Deng Y, Cooper DL: Chemoimmunotherapy and withdrawal of immunosupression for monomorphic posttransplant lymphoproliferative disorders. Clin Lymphoma Myeloma Leuk 2013;13:716-720.
[PubMed]
26.
Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G, Morschhauser F, Jaccard A, LamyT,Leithäuser M, Zimmermann H, AnagnostopoulosI, Raphael M, Riess H, Choquet S; German PTLD Study Group; European PTLD Network: Sequential treatment with rituximab followed by CHOP chemotherapy in adult B cell post-transplant lymphoproliferative disorder (PTLD): The prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012;13:196-206.
[PubMed]
27.
Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA: Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: Results of a phase II trial. Cancer 2005;104:1661-1667.
[PubMed]
28.
Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P, Carret AS, Bouscary D, Faye A, Bourbigot B, Reguerre Y, Stoppa AM, Bourquard P,Hurault de Ligny B, Dubief F, Mathieu-Boue A, Leblond V: Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Ann Oncol 2000;11(Suppl 1):113-116.
[PubMed]
29.
Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD: Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005;5:2894-2900.
[PubMed]
30.
Perrine SP, Hermine O, Small T, Suarez F, O'Reilly R, Boulad F, Fingeroth J, Askin M, Levy A, Mentzer SJ, Di Nicola M, Gianni AM, Klein C, Horwitz S,Faller DV: A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007;109:2571-2578.
[PubMed]
31.
Ricciardelli I, Blundell MP, Brewin J, Pule M, Amrolia PJ: Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells. Blood 2014;124:2514-2522.
[PubMed]
32.
Bierman PJ, Vose JM, Langnas AN, Rifkin RM, Hauke RJ, Smir BN, Greiner TC: Hodgkin's disease following solid organ transplantation. Ann Oncol 1996;7:265-270.
[PubMed]
You do not currently have access to this content.